Contemporary Management of 1-4 Brain Metastases
- PMID: 30319962
- PMCID: PMC6165904
- DOI: 10.3389/fonc.2018.00385
Contemporary Management of 1-4 Brain Metastases
Abstract
Brain metastases remain the most common neurologic complication of cancer. With improvement in surveillance and systemic therapy, patients with limited CNS disease are living longer after diagnosis, thus influencing the importance of optimal radiation treatment in order to maximize local control and minimize morbidity. In patients with a limited number of brain metastases, stereotactic radiosurgery is more recently seen as an appropriate sole modality for management with excellent local control. As newer systemic therapies emerge and with the advent of immunotherapies and targeted therapies for metastatic CNS disease, further research is needed in the optimal timing and sequencing of these modalities.
Keywords: brain metastases (BM); radiation therapy (XRT); review (article); stereotactic radiosurgery (SRS); systemic therapy.
References
-
- Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet (2004) 363:1665–72. 10.1016/S0140-6736(04)16250-8 - DOI - PubMed
-
- Wen PY, Loeffler JS. Management of brain metastases. Oncology (1999) 13:941–54, 957–61; discussion: 961–2. - PubMed
-
- Suh JHCS, Peereboom DP, Barnett GH. Metastatic cancer to brain. In: DeVita VT, Lawrence TS, Rosenberg S. editiors. Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed Philadelphia, PA: Wolters Kluwer; (2015). p. 1832–1844.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
